A new research paper was published in Oncotarget’s Volume 14 on December 20, 2023, entitled, “The pharmacodynamic and mechanistic foundation for the antineoplastic effects of GFH009, a potent and highly selective CDK9 inhibitor for the treatment of hematologic malignancies.” The study aimed to summarize current knowledge underlying the mechanism of action (MOA) of GFH009, a potent, highly selective CDK9 small molecule inhibitor, and explain its robust anti-cancer activity. The research showed that GFH009 demonstrated antiproliferative activity in assorted HHM-derived cell lines, inducing apoptosis at IC50 values below 0.2 μM in 7/10 lines tested. The results mechanistically establish CDK9 as a targetable vulnerability in assorted HHMs, supporting the rationale for ongoing clinical studies with this agent in acute myeloid leukemia and other HHMs.
Source link
GFH009 disrupts growth signals and triggers apoptosis in hematologic malignancies
